相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1949
进行中（未招募）
1
20.0%
招募中
2
40.0%
Unknown
2
40.0%
暂无批准数据
- Researchers identified the azc biosynthetic gene cluster that is necessary and sufficient for assembling the 1,3,5-triazine nucleobase of the anticancer drug 5-azacytidine. - The pathway hinges on AzcA, a cupin domain-containing enzyme that cleaves and reassembles the pyrimidine ring into a triazine through enzymatic skeletal editing. - AzcE, a GTP cyclohydrolase, and the thiamine pyrophosphate-dependent AzcB/C pair complete the cascade, which was resolved with X-ray crystallography, cryo-EM and DFT calculations. - The findings could enable biocatalytic or fermentative manufacturing of 5-azacytidine and guide genome mining for new triazine natural products.
- A phase 3 trial (JCOG1019) reveals watchful waiting is non-inferior to BCG for relapse-free survival in high-grade T1 bladder cancer patients with no residual tumor after a second TUR. - The study demonstrated similar overall survival and metastasis-free survival between the watchful waiting and BCG groups, suggesting comparable long-term outcomes. - Watchful waiting may reduce the need for BCG treatment in select patients, potentially alleviating BCG shortage issues and decreasing treatment-related adverse events. - Findings suggest watchful waiting could be a new standard of care for high-grade T1 bladder cancer patients with no residual tumor after a second TUR.
